Inclusion Criteria:  Primary hypercholesterolaemia (heterozygous familial or non-familial) or mixed dyslipidaemia AND confirmed vascular disease(*) AND other regular risk factors(**), OR confirmed familial heterozygous hypercholesterolaemia Documented maximum dietary and drug lipid-lowering therapy within the last 12 months Inadequate reduction of low-density lipoprotein cholesterol (LDL-C) despite maximum possible dietary and lipid-lowering therapy The decision of the treating physician to use the PRALUENT® 2 ml SYDNEY auto-injector regardless of study enrolment No previous therapy with a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor OR prior treatment with a PCSK9 inhibitor every 2 weeks (Q2W) or monthly (Q4W) Signed Informed Consent Form  (*) Coronary heart disease (CHD), cerebrovascular manifestation, peripheral arterial occlusive disease (PAOD)  (**) For cardiovascular events (e.g. diabetes mellitus, renal function glomerular filtration rate (GFR) < 60 ml/min)  Exclusion Criteria:  Planned or existing pregnancy, cancer, drug or alcohol abuse, dementia, or general inability to understand the content of the observational study Existing treatment by lipid apheresis Age < 18 years Contraindications to treatment with alirocumab (PRALUENT®) according to the SmPC Current participation in a clinical study  The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.